http://www.ftrintl.com/ FTR International Inc. is a an award-winning and highly innovative Union general contracting, engineering, and construction management firm that has successively proven its exceptional ethic in the successful delivery of over 100 multi-million dollar projects since our initiation in 1984. With offices in Irvine and Los Angeles, California, FTR prides itself with a diverse public works and private project portfolio, totaling billions of dollars' worth of construction costs in General Contracting, Design/Build and Construction Management delivery. Our diverse project portfolio includes state-of-the-art science laboratories, health centers, educational institutions, aviation terminals, art and theater facilities, ultra-modern mass transit stations, port security services, complex water reclamations, environmental sewage treatment facilities, and electrical power distribution centers and our industry reach extends to more than sixty public agencies.
At Gundersen Lutheran Health System’s Bariatric Surgery Center, three bariatric surgeons perform about 150 weight-loss surgeries each year. With exceptional outcomes, Gundersen Lutheran has been named a Center of Excellence and Level 1 Accredited Bariatric Center*.
“When people are considering weight-loss surgery, they should know an organization’s success rates,” explains Gundersen Lutheran surgeon Shanu N. Kothari, MD. “We collect and carefully review data on our surgeries and change treatment based on outcomes.”
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/gundluth/49125/
Miramar Labs today announced that the miraDry System for the treatment of primary axillary hyperhidrosis, commonly known as excessive underarm sweat, is now available to select physicians in the U.S. The miraDry procedure provides a safe and lasting solution for this debilitating condition.
The U.S. Food & Drug Administration granted clearance for miraDry following a robust, randomized, blinded clinical study that involved 120 patients at seven clinics and followed them 12-months post treatment. The miraDry System delivers energy non-invasively to the area under the arm where the sweat glands reside which creates localized heat to destroy and eliminate the glands. Since sweat glands do not regenerate, results are lasting.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54021-miramar-labs-miradry-treat-excessive-underarm-sweat-axillary-hyperhidrosis
It’s not every day a 75-year-old company re-defines its brand icon. Water treatment leader Culligan International is doing just that with an update to its famous “Hey Culligan Man!” persona. A new website at culligan.com (culligan.ca in Canada) features a new Culligan Man and is loaded with information on water quality and water treatment solutions for homeowners and businesses. The initiatives cap the company’s 75th anniversary year.
Introduced in 1958, “Hey, Culligan Man!” remains one of the most recognized advertising slogans and an important link between customers and the company’s network of over 800 dealers in 90 countries worldwide.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53999-culligan-celebrates-75-years-with-hey-culligan-man-update-and-new-website
New findings from the St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project (PCGP) have helped identify the mechanism that makes the childhood eye tumor retinoblastoma so aggressive. The discovery explains why the tumor develops so rapidly while other cancers can take years or even decades to form.
The finding also led investigators to a new treatment target and possible therapy for the rare childhood tumor of the retina, the light-sensing tissue at the back of the eye. The study appears in the January 11 advance online edition of the scientific journal Nature.
To view Multimedia News Release, go to http://www.multivu.com/mnr/46767-st-jude-genome-project-treatment-childhood-eye-tumor-retinoblastoma
Symptoms improved significantly in adults with the bleeding disorder hemophilia B following a single treatment with gene therapy developed by researchers at St. Jude Children’s Research Hospital in Memphis and demonstrated to be safe in a clinical trial conducted at the University College London (UCL) in the U.K.
The findings of the six-person study mark the first proof that gene therapy can reduce disabling, painful bleeding episodes in patients with the inherited blood disorder. Results of the Phase I study appear in the December 10 online edition of the New England Journal of Medicine. The research is also scheduled to be presented December 11 at the 53rd annual meeting of the American Society of Hematology in San Diego.
To view Multimedia News Release, go to http://www.multivu.com/mnr/46766-st-jude-children-s-research-hospital-gene-therapy-bleeding-disorder
International treatment guidelines – from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) – have advised that prevention of exacerbations should be a cornerstone of COPD management, placing equal emphasis on the management of future risk as it does on treatment of COPD symptoms.1 This is also confirmed in the latest data on the impact of season on the frequency of COPD exacerbations, showing an almost two-fold increase in the winter months. This is contributing to the increased morbidity seen during the festive season.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/nycomedtakeda/52782/
Famed dancer, actress, and director Debbie Allen has teamed up with Medtronic, Inc. (NYSE: MDT) today to kick off “Join the Pace Makers,” a national campaign designed to empower people with a condition called bradycardia, also known as a slow heartbeat, to learn about their available treatment options so that they can have an informed conversation with their doctor.
People living with bradycardia can experience a number of symptoms ranging from general lethargy and shortness of breath to fainting or syncope. There are a number of treatment options available, including medication therapy and implanting a pacemaker, which delivers electrical pulses to help regulate a person’s heartbeat.
To view Multimedia News Release, go to http://www.multivu.com/mnr/52990-debbie-allen-and-medtronic-join-the-pace-makers
On October 21st, 2011, Lancôme invites customers to experience the “Beauty of Giving” by celebrating Genes Day, a one-day national event Lancôme began in 2010 to support St. Jude Children’s Research Hospital, one of the world’s premier centers for the research and treatment of pediatric cancer and other catastrophic childhood diseases. On this day, Lancôme will donate $7 from the sale of every bottle of Génifique Youth Activating Concentrate to St. Jude. (This is in addition to special promotions and events nationwide surrounding Genes Day throughout the month of October.)
To view Multimedia News Release, go to http://www.multivu.com/mnr/52300-lancome-genes-day-2011-st-jude-julia-roberts-genifique-beauty-of-giving
The Sanford Guide, recognized as the essential reference for infectious disease treatment, announced the release of its first mobile app for the iPhone, iPod touch and iPad. The Sanford Guide App, available on Apple’s App Store for $29.99, contains the comprehensive guidelines and recommendations featured in the well-known pocket-size guides used by health care professionals in treatment decision making for over 40 years.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/sanfordguide/50808/
Dendreon Corporation (Nasdaq: DNDN) announced significant milestones that support broad availability for on-label use of PROVENGE® (sipuleucel-T), the first autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer (mCRPC).
To view Multimedia News Release, go to http://www.multivu.com/mnr/50924-dendreon-provenge-cellular-immunotherapy
